Group 1 - The company, Changqing Technology, focuses on the high polymer new materials segment within the fine chemical industry, specializing in special monomers and dedicated additives that enhance the performance and functionality of downstream materials [2] - The downstream applications of the company's products span multiple polymer material processing and manufacturing fields, indicating a wide and diverse range of end-use applications [2] - The application of related products in the M9 resin field depends on the specific production plans and formulation designs of downstream customers, who make autonomous decisions [2] Group 2 - The company aims to leverage its core technological accumulation and diversified product matrix to iteratively upgrade product performance, responding deeply to the customized needs of downstream customers [2] - The company seeks to further consolidate and enhance its differentiated competitive advantage in the high polymer new materials segment [2]

Group 1 - The company has successfully completed the debugging of production processes and equipment for its Phase Seven project, which is now ready for production [2] - The launch of the Phase Seven production line will significantly expand the company's core production capacity, optimize its product matrix structure, and strengthen its competitive position in the key materials sector of the polymer new materials industry [2] - The company is actively engaging in market connections and expanding its customer base related to the Phase Seven project, with plans to disclose relevant order and performance information in accordance with legal and regulatory requirements [2] Group 2 - The company's "Special Polymer Additives and Electronic Materials Manufacturing Project" is progressing as planned, with production lines being completed and gradually put into operation [2] - Some products from this project have already been sent to customers for sampling or have resulted in orders [2]

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - Changqing Technology (603125.SH) has completed the debugging of production processes and machinery for its Phase Seven project, which is now ready for formal production, aligning with the company's strategic development needs and benefiting all shareholders [1] Group 1 - The Phase Seven project production line will expand the company's capacity and enhance its product matrix [1] - The project strengthens the company's key material layout in the high polymer new materials industry [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏常青树新材料科技股份有限公司 证券代码：603125 证券简称：常青科技 公告编号：2025-077 江苏常青树新材料科技股份有限公司 关于七期（特种高分子单体二期）项目投产的公告 江苏常青树新材料科技股份有限公司（以下简称"公司"）以自有资金投资 建设的七期（特种高分子单体二期）项目（以下简称"七期项目"）已于 2025 年 5 月底试生产，具体内容详见公司于 2025 年 5 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于七期（特种高分子单体二期）项目试生产的公 告》（公告编号：2025-042）。 经过前期的试生产，截至本公告日，七期项目已完成对生产工艺及机器设备 的调试，具备正式投产条件。七期项目生产线投产后将扩大公司产能、完善公司 产品矩阵，强化公司在高分子新材料产业的关键材料布局，符合公司战略发展需 要和全体股东的利益。七期项目生产线投产后的预期效益可能受宏观经济与市场 需求变化等因素的影响，敬请广大投资者谨慎决策，注意投资风险。 ...

江苏常青树新材料科技股份有限公司 证券代码：603125 证券简称：常青科技 公告编号：2025-078 江苏常青树新材料科技股份有限公司 关于使用暂时闲置自有资金进行现金管理到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏常青树新材料科技股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的第二届董事会第十次会议及第二届监事会第九次会议，审议通过了《关 于公司拟使用暂时闲置自有资金进行现金管理的议案》，同意公司在不超过人民 币 50,000 万元的额度内使用闲置自有资金进行现金管理，上述额度自董事会审 议通过之日起 12 个月内可滚动计算。该事项在董事会审批权限内，无须提交股 东会审议。 二、截至本公告日，连续 12 个月内滚动使用自有资金现金管理的情况 一、使用闲置自有资金进行现金管理到期赎回的情况 序 号 受托方 产品名称 产品性质 投资 金额 （万元） 预计年 化收益 率 产品 期限 起息日 到期日 实际 收益 （万元） 1. 中国光大 银行股份 有限公司 2025年挂钩汇率对公 ...

Core Viewpoint - Changqing Technology (603125.SH) has announced that its Phase Seven project (Special High Polymer Monomer Phase II) has commenced trial production by the end of May 2025, marking a significant step in expanding its production capacity and enhancing its product matrix in the high polymer new materials industry [1] Group 1 - The Phase Seven project has completed the debugging of production processes and machinery, meeting the conditions for formal production [1] - The production line's launch will enhance the company's capacity and strengthen its strategic positioning in key materials within the high polymer new materials sector [1] - The project aligns with the company's strategic development needs and benefits all shareholders [1]

Core Viewpoint - Changqing Technology (603125) announced that its Phase 7 project (Special High Polymer Monomer Phase II) has completed trial production and is ready for formal production as of the end of May 2025 [1] Group 1 - The Phase 7 project is funded by the company's own resources [1] - The project has undergone adjustments to production processes and machinery [1] - The company is now prepared for official production following successful trial runs [1]

Core Viewpoint - Changqing Technology (603125.SH) has announced that its Phase Seven project, focused on special high polymer monomers, has commenced trial production by the end of May 2025, marking a significant step in its operational capacity and strategic development [1] Group 1 - The Phase Seven project has completed the debugging of production processes and machinery, meeting the conditions for formal production [1] - The production line's launch will expand the company's capacity and enhance its product matrix, reinforcing its position in the high polymer new materials industry [1] - The project aligns with the company's strategic development needs and benefits all shareholders [1]

Group 1 - The core viewpoint of the article is that Changqing Technology (603125) is progressing as planned with its "special polymer materials additives and electronic specialty materials manufacturing project" [1] - The company has indicated that relevant production lines have been gradually completed and are being put into use [1]